In their effort to answer a decades-old biological question about how the hepatitis B virus is able to establish infection of liver cells, research led by Weill Cornell Medicine, Memorial Sloan Kettering Cancer Center and The Rockefeller University identified a vulnerability that opens the door to new treatments.